Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
1.470
-0.140 (-8.70%)
At close: Mar 28, 2025, 4:00 PM
1.498
+0.028 (1.92%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Tango Therapeutics Revenue
In the year 2024, Tango Therapeutics had annual revenue of $42.07M with 15.17% growth. Tango Therapeutics had revenue of $4.12M in the quarter ending December 31, 2024, a decrease of -24.19%.
Revenue (ttm)
$42.07M
Revenue Growth
+15.17%
P/S Ratio
3.82
Revenue / Employee
$271,413
Employees
155
Market Cap
158.92M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TNGX News
- 5 days ago - Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire
- 4 weeks ago - Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights - GlobeNewsWire
- 2 months ago - Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - GlobeNewsWire
- 2 months ago - Tango Therapeutics: Chance For A Short Squeeze - Seeking Alpha
- 4 months ago - Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 months ago - Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 5 months ago - Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights - Business Wire
- 5 months ago - Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program - Business Wire